Skip to main content

Table 5 Initial source for disease progression: time to progression

From: Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression

 

Anatomic site of disease progression

 

TTP (months) **

Bone (BSLA only)

Visceral disease

Lymph node

Multiple sites*

p-value

Visceral involvement

3.0 (2.1–3.6)

2.8 (1.6–3.1)

3.1

2.1 (1.6–3.2)

0.8639

No visceral involvement

3.3 (2.9–4.4)

4.2 (3.3–4.9)

3.0 (1.6–4.4)

3.2 (3.0–4.4)

0.3968

  1. * Multiple sites: initial disease progression by RECIST which involves more than one type of anatomic site or simultaneous progression by RECIST and BSLA
  2. aData is the median with interquartile in parentheses
  3. TTP Time to progression